Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
These drugs support but do not substitute for insulin therapy in people with T1D
We evaluate biosimilars for efficacy, safety, stability and supplychain confidence to determine where they fit within our approach to specialty drug management and broader formulary strategy
Then, GPR43 (50 nM), GPR109a (50 nM), and NC siRNA (50 nM) were delivered into the HepG2 cells (~40% confluent density) and cultured in Opti-MEM (Gibco) for 6 h, after which the transfection mixture was replaced with normal medium
A qualified healthcare provider should evaluate any gaps in your treatment and adjust your protocol accordingly
US$ 27.59
US$ 23.52
US$ 22.29
US$ 20.39
US$ 21.78
US$ 28.16
